New Zealand
Medsafe — New Zealand Medicines and Medical Devices Safety Authority (Medsafe)
New Zealand is regulated by Medsafe (the New Zealand Medicines and Medical Devices Safety Authority), a business unit of the Ministry of Health (Manatū Hauora). The framework is the Medicines Act 1981 and Medicines Regulations 1984, with detailed New Zealand Regulatory Guidelines for Medicines (NZRGM, currently Edition 6.18) governing dossier format, evaluation procedures and lifecycle. Medsafe operates a tiered evaluation system for New Medicine Applications (NMAs) and Changed Medicine Notifications (CMNs), categorised by risk (Higher / Intermediate / Lower) and procedure (full / abbreviated / priority / provisional). Reliance is central to Medsafe's operating model: the Abbreviated Evaluation Procedure relies on prior assessment by recognised overseas regulators (US FDA, EMA, MHRA, Health Canada, TGA, Swissmedic) and reduces the initial evaluation target from 200 to 100 calendar days. Section 23 (full consent), Section 24 (provisional consent), and Section 29 (supply of unapproved medicines) form the backbone of the supply framework. Medsafe is not a PIC/S member and does not conduct overseas GMP inspections directly — it relies on PIC/S evidence from recognised authorities. Reimbursement is the responsibility of Pharmac (Te Pātaka Whaioranga — Pharmaceutical Management Agency), which manages the Pharmaceutical Schedule under a fixed annual budget. Pharmac uses cost-utility analysis (QALY-based) and competitive tendering to negotiate prices and confidential rebates with suppliers; only medicines listed on the Schedule are publicly funded in the community and in DHB / Health NZ hospitals.
About the authority
Medsafe is a business unit of the Ministry of Health (Manatū Hauora) responsible for the regulation of therapeutic products in New Zealand under the Medicines Act 1981 and Medicines Regulations 1984. Key functions include evaluation and approval of medicines (Section 20–24 consents), Section 29 notifications for unapproved medicines, GMP licensing of New Zealand manufacturers, pharmacovigilance (CARM — Centre for Adverse Reactions Monitoring at the University of Otago), clinical trial oversight under SCOTT (Standing Committee on Therapeutic Trials), and post-market surveillance. Medsafe is a member of the ACSS Consortium and uses work-sharing arrangements with TGA, Health Canada, HSA Singapore, Swissmedic and MHRA.
International affiliations
Reliance & recognition
Reliance is central to Medsafe's operating model. The Abbreviated Evaluation Procedure halves the initial evaluation target (100 vs 200 calendar days) by relying on assessment reports from recognised overseas regulators. New Zealand is also a participating member of the ACSS Consortium (Australia–Canada–Singapore–Switzerland–UK), which supports work-sharing and information exchange across these regulators.
Compare New Zealand side-by-side
Benchmark timelines, fees and pathway requirements against another market.
Other Asia-Pacific markets
Same structure. Same source-citation standard.